Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$142.44M+166.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Claypoole
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 960
- Beta
- 0.62
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.80
Financials
Revenue
$142.44M+166.9%Net Income
$5.99MEBITDA
$20.23M+844.5%Free Cash Flow
$20.32MEPS (diluted)
$0.08Shares Outstanding (diluted)
72.49M+27.6%Operating Expenses
$86.38MCash & Debt
$30.71MReturn of Capital
$0.00Revenue by Segment (annual)
$568.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $568.09M | $22.73M | $0.34 |
| 2024 | $573.28M | $-33.54M | $-0.52 |
| 2023 | $512.35M | $-156.23M | $-2.49 |
| 2022 | $512.12M | $-158.70M | $-2.59 |
| 2021 | $430.90M | $19.38M | $0.43 |
| 2020 | $321.16M | $16.41M | $0.44 |
| 2019 | $340.14M | $6.85M | $0.12 |
| 2018 | $319.18M | $-12.21M | $-0.22 |
| 2017 | $292.06M | $-1.64M | $-0.13 |
| 2016 | $274.50M | $-17.95M | $-0.41 |
| 2015 | $253.65M | $-34.11M | $-0.69 |
| 2014 | $242.89M | $-12.90M | $-0.30 |
| 2013 | $232.38M | $-22.37M | $-0.47 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.50
- Implied price
- $11.03
- Return from $9.88
- 2.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5.48 — -44.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -2.0% | -13.0% | -9.9% | -7.2% | -4.8% | -2.7% |
| 3.0% | -8.5% | -5.3% | -2.5% | 0.0% | 2.3% |
| 8.0% | -4.1% | -0.7% | 2.2% | 4.9% | 7.3% |
| 13.0% | 0.4% | 3.9% | 7.0% | 9.7% | 12.2% |
| 18.0% | 4.8% | 8.5% | 11.7% | 14.6% | 17.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+16.67%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·19d ago·Positive
Bioventus Inc. (BVS) Q3 2026 Earnings Call Transcript Bioventus Inc. ( BVS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton - Senior VP & CFO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Lawrence Solow - CJS Securities, Inc. Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Michael …
View source ↗ - Newszacks.com·20d ago·Neutral
Bioventus (BVS) Matches Q3 Earnings Estimates Bioventus (BVS) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.15 per share a year ago.
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
Bioventus Q3 Earnings Call Highlights Bioventus NASDAQ: BVS reported third-quarter revenue growth of 3% as strength in its Pain Treatments business, Ultrasonics operation and international markets was partly offset by softness in bone graft substitutes, or BGS, within Surgical Solutions.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Bioventus Reports Third Quarter Financial Results DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 26, 2026.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026 DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2026 after the market closes on Monday, November 2, 2026. The Company's management will host a conference call at 4:30 p.m. Eastern Time that same day to dis…
View source ↗ - Newsseekingalpha.com·62d ago·Positive
Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale Bioventus leverages cash from established products to reduce debt and fund commercial expansion, supporting a bullish outlook. BVS benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. Execution focus is on demonstrating sustained cash flows, successful new product adoption, and repeat physician usage, not just early launch revenue.
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $0.24 per share
Typical surprise +9.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$0.17 vs $0.15beat
- Wed, Aug 5$0.22 vs $0.22beat
- Wed, May 6$0.15 vs $0.09beat
- Thu, Mar 5$0.24 vs $0.22beat
- Tue, Nov 4$0.15 vs $0.21miss
- Wed, Aug 6$0.21 vs $0.22miss
Estimates and results for BVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BVS officers and directors.
- Bought
- —
- Sold
- $312k
0 trades
3 trades
- Mcmurry-heath Michellesold
- Nohra Guy Psold
- Mcmurry-heath Michellesold
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BVS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
